Edgewise Therapeutics (EWTX): EDG-7500 MoA update provides context for clinical profile

Today's EWTX update further defines EDG-7500's differentiated mechanism and provides additional context for its emerging clinical profile. EWTX identified the regulatory light chain (RLC) as EDG-7500's target after screening more than 7,000 candidates for positive lusitropic activity without associated systolic liabilities. Unlike cardiac myosin inhibitors, EDG-7500 is designed to alter the timing of contraction and relaxation rather than broadly reduce myosin activity, slowing early systolic pressure development to potentially reduce LVOT obstruction while preserving overall systolic performance. Lusitropic effects emerged at lower exposures and appeared to precede peak gradient reduction;